

## **Fulcrum Therapeutics to Host First Quarter 2022 Financial Results Conference Call and Webcast on Monday, May 9, 2022 at 8:00 a.m. ET**

May 2, 2022 at 8:01 AM EDT

CAMBRIDGE, Mass., May 02, 2022 (GLOBE NEWSWIRE) -- [Fulcrum Therapeutics, Inc.](#)® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that its first quarter 2022 financial results will be released on Monday, May 9, 2022 before the U.S. financial markets open. Management will host a conference call and webcast at 8:00 a.m. ET to discuss the results and provide an update on recent corporate developments.

### **Dial-in Number**

U.S./Canada Dial-in Number: 800-527-6973

International Dial-in Number: 470-495-9162

Conference ID: 1129907

Replay Dial-in Number: 855-859-2056

Replay International Dial-in Number: 404-537-3406

Conference ID: 1129907

An audio webcast will be accessible through the Investor Relations section of the company's website <https://ir.fulcrumtx.com/events-and-presentations>. Following the live webcast, an archived replay will also be available.

### **About Fulcrum Therapeutics**

Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum's two lead programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD), and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia. Fulcrum's proprietary product engine, FulcrumSeek™, identifies drug targets that can modulate gene expression to treat the known root cause of gene mis-expression. For more information, visit [www.fulcrumtx.com](http://www.fulcrumtx.com) and follow us on Twitter @FulcrumTx and [LinkedIn](#).

### **Contacts:**

Naomi Aoki  
Senior Vice President, Corporate Communications and  
Investor Relations  
naoki@fulcrumtx.com

Stephanie Ascher  
Stern Investor Relations, Inc.  
stephanie.ascher@sternir.com  
212-362-1200